Edition:
United States

Eli Lilly and Co (LLY.N)

LLY.N on New York Stock Exchange

78.97USD
16 Feb 2018
Change (% chg)

$0.95 (+1.22%)
Prev Close
$78.02
Open
$77.95
Day's High
$79.64
Day's Low
$77.95
Volume
1,595,745
Avg. Vol
1,120,265
52-wk High
$89.07
52-wk Low
$73.70

Select another date:

Tue, Feb 6 2018

BRIEF-Adocia Files Additional Arbitration Claims Against Eli Lilly & Company​

* ‍ADOCIA FILES ADDITIONAL ARBITRATION CLAIMS AGAINST ELI LILLY & COMPANY​

BRIEF-Eli Lilly plans to deploy around $9 bln of global cash

* SEES 2018 EFFECTIVE TAX RATE OF 18%, DOWN FROM PREVIOUS NON-GAAP EXPECTATION OF 21.5%

BRIEF-NSAV Subsidiary Signs Agreement With Eli Lilly

* NSAV SUBSIDIARY SIGNS MAJOR AGREEMENT WITH ELI LILLY AND COMPANY

Lilly's 2018 forecast beats on strength of new drugs

Eli Lilly and Co on Wednesday forecast 2018 profit and revenue ahead of Wall Street estimates on strong demand for recently launched drugs such as Trulicity and Taltz.

Lilly forecasts 2018 profit largely above estimates

Dec 13 Eli Lilly and Co on Wednesday forecast 2018 earnings largely above analysts' estimates in part due to strong demand for recently launched products such as diabetes drug Trulicity and psoriasis drug Taltz.

BRIEF-FDA Accepts Biologics License Application (BLA) To Review Galcanezumab For The Prevention Of Migraine In Adults

* FDA ACCEPTS BIOLOGICS LICENSE APPLICATION (BLA) TO REVIEW GALCANEZUMAB FOR THE PREVENTION OF MIGRAINE IN ADULTS

BRIEF-Novo Nordisk expects to launch new diabetes drug in Japan during H1 2018

Dec 6 NOVO NORDISK A/S CHIEF SCIENTIFIC OFFICER MADS KROGSGAARD THOMSEN MADE FOLLOWING COMMENTS DURING AN INVESTOR CALL FOLLOWING U.S. APPROVAL OF DIABETES DRUG OZEMPIC:

FDA approves Novo Nordisk diabetes drug Ozempic

The U.S. Food and Drug Administration on Tuesday approved Novo Nordisk A/S's diabetes drug Ozempic, setting the stage for a heated battle with Eli Lilly & Co's Trulicity.

UPDATE 3-U.S. FDA approves Novo Nordisk diabetes drug Ozempic

Dec 5 The U.S. Food and Drug Administration on Tuesday approved Novo Nordisk A/S's diabetes drug Ozempic, setting the stage for a heated battle with Eli Lilly & Co's Trulicity.

BRIEF-Eli Lilly And Co reports 17.5 pct passive stake in Leap Therapeutics ‍​as of Nov 14

* Eli Lilly And Co reports 17.5 percent passive stake in Leap Therapeutics Inc‍​ ‍​as of November 14 - SEC Filing Source text: (http://bit.ly/2BcO2L7) Further company coverage:

Select another date: